Overcoming drug resistance with specific nano scales to targeted therapy: Focused on metastatic cancers

被引:2
|
作者
Kadhum, Wesam R. [1 ,2 ]
Majeed, Ali A. [3 ]
Saleh, Raed Obaid [4 ]
Ali, Eyhab [5 ]
Alhajlah, Sharif [6 ]
Alwaily, Enas R. [7 ]
Mustafa, Yasser Fakri [8 ]
Ghildiyal, Pallavi [9 ]
Alawadi, Ahmed [10 ,11 ,12 ]
Alsalamy, Ali [13 ]
机构
[1] Kut Univ Coll, Dept Pharm, Kut 52001, Wasit, Iraq
[2] Kut Univ Coll, Adv Res Ctr, Kut 52001, Wasit, Iraq
[3] Univ Kufa, Fac Sci, Dept Pathol Anal, Najaf, Iraq
[4] Al Maarif Univ Coll, Dept Med Lab Tech, Al Anbar, Iraq
[5] Al Zahraa Univ Women, Pharm Dept, Karbala, Iraq
[6] Shaqra Univ, Coll Appl Med Sci, Dept Med Labs, Shaqra 11961, Saudi Arabia
[7] Al Ayen Univ, Coll Pharm, Microbiol Res Grp, Thi Qar, Iraq
[8] Univ Mosul, Coll Pharm, Dept Pharmaceut Chem, Mosul, Iraq
[9] Uttaranchal Univ, Uttaranchal Inst Pharmaceut Sci, Dehra Dun, Uttarakhand, India
[10] Islamic Univ, Coll Tech Engn, Najaf, Iraq
[11] Islamic Univ Al Diwaniyah, Coll Tech Engn, Al Diwaniyah, Iraq
[12] Islamic Univ Babylon, Coll Tech Engn, Babylon, Iraq
[13] Imam Jaafar Al Sadiq Univ, Coll Tech Engn, Al Muthanna, Iraq
关键词
Targeted Therapy; Metastatic cancer; Scales; Nano drug; Signaling; SOLID LIPID NANOPARTICLES; ENHANCED PERMEABILITY; REXIN-G; GENETIC-HETEROGENEITY; INTRINSIC RESISTANCE; MULTIDRUG-RESISTANCE; DELIVERY SYSTEMS; SINGLE-AGENT; LUNG-CANCER; IN-VITRO;
D O I
10.1016/j.prp.2024.155137
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
Metastatic cancer, which accounts for the majority of cancer fatalities, is a difficult illness to treat. Currently used cancer treatments include radiation therapy, chemotherapy, surgery, and targeted treatment (immune, gene, and hormonal). The disadvantages of these treatments include a high risk of tumor recurrence and surgical complications that may result in permanent deformities. On the other hand, most chemotherapy drugs are small molecules, which usually have unfavorable side effects, low absorption, poor selectivity, and multi-drug resistance. Anticancer drugs can be delivered precisely to the cancer spot by encapsulating them to reduce side effects. Stimuli-responsive nanocarriers can be used for drug release at cancer sites and provide target-specific delivery. As previously stated, metastasis is the primary cause of cancer-related mortality. We have evaluated the usage of nano-medications in the treatment of some metastatic tumors.
引用
收藏
页数:10
相关论文
共 50 条
  • [1] Overcoming resistance to targeted therapy with immunotherapy and combination therapy for metastatic melanoma
    Keller, Hilary R.
    Zhang, Xin
    Li, Li
    Schaider, Helmut
    Wells, James W.
    ONCOTARGET, 2017, 8 (43) : 75675 - 75686
  • [2] Recent advances in overcoming resistance to targeted therapy in KRAS mutant cancers
    Adachi, Yuta
    Niitsu, Hiroaki
    Ebi, Hiromichi
    CANCER SCIENCE, 2023, 114 : 986 - 986
  • [3] Nanomedicine for targeted cancer therapy: Towards the overcoming of drug resistance
    Shapira, Alina
    Livney, Yoav D.
    Broxterman, Henk J.
    Assaraf, Yehuda G.
    DRUG RESISTANCE UPDATES, 2011, 14 (03) : 150 - 163
  • [4] Targeted Cancer Therapy; Nanotechnology Approaches for Overcoming Drug Resistance
    Gao, Yan
    Shen, Jacson K.
    Milane, Lara
    Hornicek, Francis J.
    Amiji, Mansoor M.
    Duan, Zhenfeng
    CURRENT MEDICINAL CHEMISTRY, 2015, 22 (11) : 1335 - 1347
  • [5] Targeted therapy: overcoming drug resistance with clinical cancer genome
    Ziogas, Demosthenes E.
    Katsios, Christos S.
    Tzaphlidou, Margaret
    Roukos, Dimitrios H.
    EXPERT REVIEW OF ANTICANCER THERAPY, 2012, 12 (07) : 861 - 864
  • [6] Sequential therapy with targeted agents in metastatic renal cell carcinoma: beyond second-line and overcoming drug resistance
    Khattak, Muhammad
    Larkin, James
    WORLD JOURNAL OF UROLOGY, 2014, 32 (01) : 19 - 29
  • [7] Sequential therapy with targeted agents in metastatic renal cell carcinoma: beyond second-line and overcoming drug resistance
    Muhammad Khattak
    James Larkin
    World Journal of Urology, 2014, 32 : 19 - 29
  • [8] Overcoming multiple drug resistance in lung cancer using siRNA targeted therapy
    Naghizadeh, Sanaz
    Mohammadi, Ali
    Baradaran, Behzad
    Mansoori, Behzad
    GENE, 2019, 714
  • [9] Overcoming drug resistance and tumor heterogeneity in gastrointestinal cancers
    Corcoran, Ryan B.
    MOLECULAR CANCER THERAPEUTICS, 2017, 16 (10)
  • [10] Overcoming Resistance to Targeted Therapy for Lung Cancer
    Govindan, Ramaswamy
    NEW ENGLAND JOURNAL OF MEDICINE, 2015, 372 (18): : 1760 - 1761